Pfizer Prevnar 13 Pneumococcal Vaccine from Canada
Prevnar 13 is a 13-valent pneumococcal conjugate vaccine used to prevent invasive disease caused by Streptococcus pneumoniae in infants and adults. It contains purified capsular polysaccharides conjugated to a carrier protein, qualifying as an immunological product under HTS 3002.15.00 due to its measured doses packaged for retail sale in pre-filled syringes.
Duty Rate — Canada → United States
0%
Rate breakdown
9903.05.860%Universal product exemption (U.S. note 52(b))
Import Tips
• Obtain FDA approval and biologics license; ensure cold chain documentation for vaccines
• Provide certificates of analysis confirming immunological activity and sterility
• Avoid misclassification as unmixed antigens by verifying retail packaging and measured doses